the pace here is really picking up...strong buy...do your own R&D and proceed after doing due diligence:
(PR NEWSWIRE) SpectruMedix Corp. Ships SCE9610 System to Major European Seed
SpectruMedix Corp. Ships SCE9610 System to Major European Seed Company Svalof
Weibull AB
STATE COLLEGE, Pa., Oct. 4 /PRNewswire/ -- SpectruMedix Corporation
(OTC Bulletin Board: SMDX) has sold its SCE9610 Genetic Analysis System to
Svalof Weibull AB, an international plant breeding company engaged in varietal
development, production and marketing of canola, peas, cereals, forage crops
and potatoes.
Based in Sweden, Svalof Weibull is one of the major seed companies in
Europe. It has a broad base of breeding lines and holds a leading position in
the world with its spring oilseed rape varieties.
"I am delighted by the dual aspects of this transaction: the sale of the
SCE9610 to Svalof Weibull not only expands our presence to the international
arena, but into the plant-breeding marketplace, as well. This is a robust,
highly reliable, fully automated system designed to make labs more efficient
and provide high quality data -- whether it's analyzing human genes or plant
genes," said Dr. Joseph Adlerstein, CEO of SpectruMedix Corp.
Svalof Weibull sells seeds to farmers -- but before they can be sold, the
company needs to be certain of the product's homogeneity. Purity of the seed
lines is determined by quality assurance procedures at the company's research
and development Nilsson-Ehle Laboratory using proprietary molecular markers.
In order to screen the large amount of material required, this process needs
to be, and is, highly automated. The integration of the SCE9610 system into
the lab will enable and enhance this automation.
Christophe Dayteg of Svalof Weibull said he expects the implementation of
the SCE9610 will increase the analysis ability to about 5,000 samples per day
-- almost three times the laboratory's current throughput.
"Svalof Weibull chose the SCE9610 system because it is the most easily
integrated and adapted into their fully automated, robotic sample preparation
system," said Dr. Thomas Kane, director of technology commercialization for
SpectruMedix Corp.
SpectruMedix develops and manufactures high-speed and high throughput DNA
sequencing and genetic analysis instrumentation for the acquisition, analysis
and management of complex genetic information and high-throughput screening,
massive parallel capillary electrophoresis systems for drug discovery. The
DNA sequencing and high-throughput screening instrumentation were developed in
part from research efforts conducted at the U.S. Department of Energy's Ames
Laboratory, which is operated by Iowa State University's Institute for
Physical Research and Technology. SpectruMedix is also involved in the
development of instrumentation and methodology to rapidly assess lung function
in all pulmonary diseases, in order to improve evaluation, diagnosis and
treatment in such patients.
Except for historical information contained herein, the statements made in
this release constitute forward-looking statements that involve certain risks
and uncertainties. Certain factors may cause actual results to differ
materially from those contained in the forward-looking statements, including
the ability of SpectruMedix to commercialize and market its instrumentation,
the availability of funding to realize SpectruMedix's plans and other risks
detailed from time to time in SpectruMedix's reports on file at the Securities
and Exchange Commission, including SpectruMedix's Form 10-KSB for the fiscal
year ended March 31, 2000. SpectruMedix disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE SpectruMedix Corporation
-0- 10/04/2000
/CONTACT: Joseph Adlerstein of SpectruMedix, 814-867-8600/
/Web site: spectrumedix.com /
(SMDX)
CO: SpectruMedix Corporation; Svalof Weibull AB
ST: Pennsylvania, Sweden
IN: BIO MTC
SU: CON |
